Cannabidiol
NERVOUS SYSTEM
Also known as: epidiolex, GWP42003-P
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Cannabidiol is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. Its mechanism of action is classified as Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2B6 Inducers and Cytochrome P450 2B6 Inhibitors. DrugCentral lists 45 molecular targets, including DRD2, CASP1 and TRPM8. Recorded indications include Lennox-Gastaut syndrome and Severe myoclonic epilepsy in infancy.
- Approval status: onp (first approved 2018 by the FDA).
- Mechanism of action: Cytochrome P450 1A2 Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors.
- Molecular targets: DRD2, CASP1, TRPM8 and PDE9A (45 listed in DrugCentral).
- Indications: Lennox-Gastaut syndrome and Severe myoclonic epilepsy in infancy.
- ATC code: N03AX24 (Other antiepileptics).
- Molecular formula: C21H30O2; molecular weight 314.47 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Lennox-Gastaut syndrome
- Severe myoclonic epilepsy in infancy
Mechanism & targets
| Mechanism of action (MoA) | Cytochrome P450 1A2 Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2C9 Inhibitors; UGT1A9 Inhibitors; UGT2B7 Inhibitors |
|---|
Molecular targets (45)
| Target | Gene | Action | Activity |
|---|---|---|---|
| D(2) dopamine receptor | DRD2 | unknown | Ki 10.18 |
| Caspase-1 | CASP1 | unknown | Kd 7.73 |
| Transient receptor potential cation channel subfamily M member 8 | TRPM8 | unknown | IC50 7.22 |
| High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A | PDE9A | unknown | IC50 6.96 |
| Sodium channel protein type 9 subunit alpha | SCN9A | blocker | IC50 6.70 |
| Cannabinoid receptor 2 | Cnr2 | unknown | Ki 6.64 |
| Equilibrative nucleoside transporter 1 | SLC29A1 | unknown | Ki 6.60 |
| Calcium-activated potassium channel subunit alpha-1 | KCNMA1 | unknown | IC50 6.55 |
| G-protein coupled receptor 55 | GPR55 | antagonist | EC50 6.35 |
| Transient receptor potential cation channel subfamily A member 1 | Trpa1 | unknown | IC50 6.35 |
| Heat sensitive channel TRPV3 | — | unknown | EC50 6.29 |
| Cholinesterase | BCHE | unknown | IC50 6.17 |
| Transient receptor potential cation channel subfamily V member 4, TrpV4 | Trpv4 | unknown | EC50 6.05 |
| 5-hydroxytryptamine receptor 2C | HTR2C | unknown | Ki 5.96 |
| Cannabinoid receptor 1 | Cnr1 | unknown | Ki 5.90 |
| Mu-type opioid receptor | OPRM1 | unknown | Ki 5.89 |
| Sodium channel protein type 4 subunit alpha | SCN4A | blocker | IC50 5.72 |
| Sodium channel protein type 10 subunit alpha | Scn10a | blocker | IC50 5.70 |
| Kappa-type opioid receptor | OPRK1 | unknown | Ki 5.64 |
| Cannabinoid receptor 1 | CNR1 | unknown | Ki 5.62 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-09-19 | EMA | — | GW Pharma (International) B.V. | Yes |
| 2018-06-25 | FDA | — | GW RESEARCH LTD | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N03AX24 | NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Seizure | 7547.1 |
| Product use in unapproved indication | 996.4 |
| Somnolence | 877.0 |
| Product dose omission issue | 595.7 |
| Hospitalisation | 492.8 |
| Product administration interrupted | 484.5 |
| Seizure cluster | 404.3 |
| Diarrhoea | 357.5 |
| Aggression | 353.6 |
| Generalised tonic-clonic seizure | 352.7 |
| Multiple-drug resistance | 301.9 |
| Atonic seizures | 297.9 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Cannabidiol is on its molecule page.
| Molecular formula | C21H30O2 |
|---|---|
| Molecular weight | 314.47 g/mol |
| CAS number | 13956-29-1 |
| InChIKey | QHMBSVQNZZTUGM-ZWKOTPCHSA-N |
| PubChem CID | 644019 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Cannabidiol used for?
DrugCentral lists the following indications for Cannabidiol: Lennox-Gastaut syndrome and Severe myoclonic epilepsy in infancy.
How does Cannabidiol work?
Cannabidiol is classified as Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2B6 Inducers and Cytochrome P450 2B6 Inhibitors; its molecular targets in DrugCentral include DRD2, CASP1, TRPM8 and PDE9A.
When was Cannabidiol first approved?
Cannabidiol was first approved by the FDA in 2018.
What is the chemical formula of Cannabidiol?
Cannabidiol has the molecular formula C21H30O2 and a molecular weight of 314.47 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5288 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL190461 — compound record and bioactivity
- PubChem CID 644019 — chemical identifiers
- DrugBank DB09061 — drug record
- FDA UNII 19GBJ60SN5 — substance identity
- DailyMed: FDA labels for Cannabidiol — current prescribing information (label search)
- UniProt P14416 (DRD2) — target protein
- UniProt P29466 (CASP1) — target protein
- UniProt Q7Z2W7 (TRPM8) — target protein
- UniProt O76083 (PDE9A) — target protein
- UniProt Q15858 (SCN9A) — target protein
- UniProt Q99808 (SLC29A1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.